<DOC>
	<DOC>NCT00286117</DOC>
	<brief_summary>The purpose of this study was to assess the difference in disease-free survival between post-menopausal women with hormone receptor-positive early breast cancer who switched from tamoxifen to anastrozole and those who continued on tamoxifen.</brief_summary>
	<brief_title>ITA - Clinical Study Comparing ARIMIDEX™ With NOLVADEX™ in Women With Breast Cancer Treated With NOLVADEX for at Least 2 Years</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Postmenopausal status; age ≤75 years; histologically confirmed invasive breast cancer with metastases in the axillary lymph nodes; oestrogen receptor status positive or unknown; primary treatment (surgery +/ radiotherapy, +/ chemotherapy) completed Clinical evidence of metastatic disease (including local or remote recurrence, even if the patient appeared to be in complete remission at the time of randomisation).</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Breast Cancer</keyword>
</DOC>